Near-infrared (NIR: 800 -1,000 nm) fluorescent probes, which activate their 2 fluorescence following interaction with functional biomolecules, are desirable for 3 noninvasive and sensitive tumor diagnosis due to minimal tissue interference. Focusing 4 on bioavailability and applicability, we developed a probe with a self-assembling 5 polymer micelle, a lactosome, encapsulating various quantities of NIR dye (IC7-1). We 6 also conjugated anti-HER2 single chain antibodies to the lactosome surface and 7 examined the probe"s capacity to detect HER2 in cells and in vivo. Micelles 8 encapsulating 20 mol% IC7-1 (hIC7L) showed 30-fold higher fluorescence ( em : 858 9 nm) after micelle denaturation compared to aqueous buffer. Furthermore, antibody 10 modification allowed specific activation of the probe (HER2-hIC7L) following 11 internalization by HER2-positive cells, with the probe concentrating in lysosomes.
amphiphilic polydepsipeptide (Fig. 1B) . As expected, IC7L showed suitable optical 1 characteristics for in vivo imaging with excitation and emission wavelengths of 830 and 2 858 nm, respectively 7 , and could visualize tumors in vivo with less accumulation in the 3 reticuloendothelial system (RES) [7] [8] [9] . However, IC7L could not distinguish tumor 4 properties such as expression of biomolecules related to malignancy since the tumor 5 accumulation occurred via the enhanced permeability and retention (EPR) effect. 6 To facilitate tumor biomolecule detection by IC7L, we sought to modify IC7L by 7 two strategies: 1) attachment of a targeting ligand on the surface of IC7L, and 2) 8 introduction of a signal activatable system that can suppress signals from non-targeted 9 tissues ( Fig. 1D ). To make IC7L an activatable probe, we applied a self-quenching 10 mechanism in which lipophilic dye is encapsulated at high concentrations in the 11 hydrophobic core of the lactosome where it forms self-stacking structures that induce a addition, since HER2 is internalized after interaction with antibodies and subsequently 1 delivered to lysosomes for degradation 12 , this process can be used to trigger probe 2 dequenching to restore fluorescence emission. Thus, HER2 is a suitable target 3 biomolecule for both probe evaluation and future therapeutic applications. In this study, we first prepared lactosomes encapsulating IC7-1 at a variety of 6 concentrations, and evaluated both their quenching and dequenching properties in in 7 vitro experiments. We found that lactosomes encapsulating 20 mol% IC7-1 functioned 8 as activatable probes, and thus named this activatable probe hIC7L with "h" indicating a 9 high dye concentration. We then conjugated an anti-HER2 single chain antibody on the 10 hydrophilic surface of hIC7L to produce HER2-hIC7L, and evaluated its effectiveness 11 as a targeting activatable NIR probe in vitro and in vivo. Since we also found that 12 several other cyanine dyes could be used similarly to IC7-1 in this activatable system, 13 we selected hCy5L (lactosome encapsulating 20 mol% Cy5) for microscopic study 14 because the Cy5 fluorescence wavelength was preferable to IC7-1 for our microscopy 15 experiments.
Methods

1
Preparation of IC7L
2 All chemicals were commercially available and of the highest purity. The 3 amphiphilic polymer of the lactosome (Fig. 1B , polysarcosine-block-poly-L-lactate 4 (PSar 70 -block-PLLA 30 ) with glycol capping at the N-terminal) was supplied by the 5 Shimadzu Corporation (Kyoto, Japan).
6
IC7L was prepared as previously described 7 . In brief, PSar 70 -block-PLLA 30 (388 7 nmol) and IC7-1-PLLA 30 (3.9 -97 nmol) dissolved in chloroform (500 l) were dripped 8 into a glass test tube. The solvent was removed under reduced pressure to form a thin 9 film on the tube wall. Phosphate buffered saline (PBS, 0.1 M, pH 7.4) was then added to 10 the test tube and heated at 82 ºC for 20 min. The resulting aqueous solution was filtered 11 through a 0.20 m Acrodisc ® syringe filter (Pall Corp, East Hills, NY). The IC7L size 12 distribution was measured at 25 ºC using a Zetasizer Nano-S90 (Malvern Instruments   13 Ltd., UK).
14
IC7L
(1 mg/ml, 100 l) with an IC7-1 concentration of 1-20 mol% was incubated 15 in 100 l PBS (0.1 M, pH 7.4) with or without sodium dodecyl sulfate (SDS, 5% final 16 concentration) for 30 min at room temperature. After incubation, 2.8 ml PBS was added 17 to the solution and the fluorescence emission spectra were measured with a fluorescence 1 Anti-HER2 single chain Fv (scFv) (4D5 C10) with a cysteine at the C-terminus was a 2 kind gift from CANON Inc. (Tokyo, Japan). Anti-HER2 scFv (300 g, 100 l PBS) was 3 added to tris(2-carboxyethyl)phosphine hydrochloride (63.7 g) and incubated for 2 hr 4 on ice before purification on a size-exclusion column (Sephadex G-50, GE Healthcare, 5 UK) to obtain the reduced form of scFv. Anti-HER2 scFv was then added to 6 maleimide-IC7L/hIC7L (1 mg/1 ml) and incubated for 4 hr on ice with protection from 7 light. After incubation, cysteine·HCl (158 g) was added and further incubated for 30 8 min on ice. The mixture was then ultracentrifuged in an Amicon ® ultra-4 Centrifugal 9 Filter Unit (100 kDa-cutoff, Millipore, UK) to obtain HER2-IC7L/hIC7L. The purity 10 was analyzed by size exclusion chromatography using a Superdex 200 10/300 GL 11 column (GE Healthcare, U.K.) equilibrated with PBS at a flow rate of 0.5 ml/min.
12
Absorbance at 215 and 830 nm was used to detect the lactosome and IC7-1, respectively, 13 which confirmed that the absorbance peaks at both wavelengths were detected 14 simultaneously in the high molecular weight fraction. The size distribution of 15 HER2-IC7L was measured at 25 °C using a Zetasizer Nano-S90 and transmission 16 electron microscopy that is described in detail in the supplementary material ( Fig. S2 ). bicinchoninic acid (BCA) assay, and then the number (molar ratio) of the anti-HER2 1 scFvs per lactosome was then calculated using the estimated molecular weight values: represented as a ratio to the dosage as follows: For the blocking study, NCI-N87 cells (2 × 10 5 cells) were treated with trastuzumab 9 (4.7 mg/1 ml RPMI1640 with 50 M BSA, 1000 mol-fold equivalent of HER2-IC7L) 10 for 15 min and HER2-IC7L (40 g) was then added. Subsequent fluorescence 11 measurements were carried out as described above. were housed under a 12-h light/12-h dark cycle and given free access to food and water.
16
The animal experiments performed in this study were conducted in accordance with 17 institutional guidelines and approved by the Kyoto University Animal Care Committee, Japan.
1 NCI-N87 cells (5 × 10 6 cells) suspended in 100 l PBS containing 50 % Geltrex 2 (Invitrogen Japan, Tokyo, Japan) were subcutaneously inoculated into the right hind 3 legs of mice (4 week old), and an in vivo imaging study was performed after a 4-week 4 growth period. In addition, for evaluation of IC7L encapsulating 20 mol% IC7-1, 5 SUIT-2 cells (5 × 10 6 cells in 100 l PBS containing 50 % Geltrex) were also 6 transplanted to the opposite side 2 weeks after the NCI-N87 transplantation. In vivo imaging study 9 HER2-IC7L or IC7L (2 mg / ml PBS, 100 l) were injected into the tumor-bearing 10 mice via the tail vein and NIR florescence images were taken using a Clairvivo OPT 11 with a 785 nm laser diode for excitation, and a 845/55 nm bandpath filter for emission.
12
During the imaging process, mice remained on the imaging stage under anesthesia using 13 2.5% isoflurane gas in oxygen (1.5 l / min). Regions of interest (ROI) were designated 14 for the tumor and background (around the neck) on the acquired images to measure 15 fluorescence intensities.
Data are represented as the mean ± S.D. Statistical analyses were performed with 1 two-way factorial ANOVA followed by a Tukey-Kramer test. Statistical analyses of the 2 in vitro blocking study and in vivo study were performed with Bartlett's test followed by 3 the Bonferroni-Holm method. A two-tailed value of p < 0.05 was considered to be 4 statistically significant. properties that were similar to hIC7L ( Fig.S1 ).
1
For the HER2-IC7L/hIC7L preparation, the particle sizes of HER2-IC7L, 2 HER2-hIC7L, IC7L and hIC7L were 31.0 ± 2.7 nm (n = 3), 30.0 ± 2.5 nm (n = 6), 30.4 3 ± 6.0 nm (n = 3) and 30.8 ± 4.7 nm (n = 6), respectively. The estimated average molar 4 ratio of anti-HER2-scFvs conjugated to an IC7L or an hIC7L were 5.6 ± 1.8 (n = 3) and 5 5.9 ± 0.9 (n = 6), respectively. The dissociation constant (K d ) of HER2-hIC7L against 6 HER2 protein was about 0.014 ± 0.012 nM (n = 4). On the other hand, hIC7L did not 7 bind to HER2 protein and a K d value could not be calculated. In vitro study 10 The uptake of probes by NCI-N87 cells (high expression levels of HER2) and 11 SUIT-2 cells (low HER2 expression levels) was examined for 6 hr after administration 12 ( Fig. 3 and 4 ). With HER2-IC7L and IC7L sorted as the always-on probes (Fig. 3) , the 13 fluorescence of NCI-N87 cells at 1 hr after HER2-IC7L addition was significantly 14 higher than that of cells treated with IC7L and eventually reached a plateau (Fig. 3A) .
15
With the activatable probes HER2-hIC7L and hIC7L ( Fig. 4) , HER2-hIC7L 16 fluorescence in NCI-N87 cells increased gradually and was significantly higher than the 17 hIC7L fluorescence in the cells 3 hr or more after addition (Fig. 4A) . In contrast, probe uptake by SUIT-2 cells ( Fig. 3B and 4B) was consistently low for all four probes, and 1 treatment with excess trastuzumab blocked uptake of HER2-hIC7L by NCI-N87 cells to 2 levels that were similar to hIC7L uptake (Fig. 4C ). Similar results were obtained with 3 BT-474 and MCF-7 cells, which express high and low levels of HER2, respectively ( Fig.   4 S5).
5
The intracellular probe localization was evaluated by fluorescence microscopy 6 using HER2-hCy5L (Cy5 was encapsulated in lactosomes instead of IC7-1), which 7 showed that the fluorescence localization was similar to the distribution of Lysotracker 8 (Fig. S4 ). 9 HER2-hIC7L increased with time and provided higher values than those of hIC7L ( Fig.   1 5D, 2.4 ± 0.2 vs. 1.8 ± 0.2 at 12 hr and 2.8 ± 0.2 vs. 2.0 ± 0.3 at 24 hr). Meanwhile, the 2 T/B ratios in the SUIT-2 tumors were unchanged regardless of the probe used (Fig. 5D,   3 2.0 ± 0.2 vs. 2.0 ± 0.2 at 12 hr and 2.2 ± 0.1 vs. 2.2 ± 0.1 at 24 hr). In addition, similar 4 in vivo fluorescence images were also obtained in BT-474 (HER2 high expressing cells) 5 and MCF-7 (HER2 low expressing cells) xenografted SCID mice (Fig. S6 ). In this study, we first showed that the IC7L fluorescence was quenched with 2 increasing concentrations of IC7-1 encapsulated in lactosomes ( Fig. 2A) . In the 3 absorbance spectra, the peak around 750 nm emerged as the concentration of IC7-1 was 4 higher in the aqueous buffer (Fig. 2C) , and indicated the formation of H-dimers 17 . 5 Furthermore, in SDS solution, the quenched IC7L fluorescence was dequenched 6 following lactosome degradation and subsequent release of the encapsulated dyes ( Fig.   7 2B). Similar results were also obtained with lactosomes that encapsulated other 8 cyanine dyes at a molar ratio of 20 mol% (Fig. S1 ). Therefore, this quenching would be 9 attributable to the effective stacking of cyanine dye molecules within the hydrophobic 10 core of the lactosome due to the probe"s high lipophilicity, and these results indicate that 11 lactosomes carrying 20 mol% of cyanine dyes can serve as activatable fluorescence 12 probes.
14
We then prepared HER2-hIC7L as a HER2-specific activatable NIR probe. The 15 particle size of this probe was similar to hIC7L. Considering the smaller size of scFv (5 16 nm) 18 compared with the lactosome (30 nm), the occupied volume of anti-HER2-scFv 17 in HER2-hIC7L was very low (presumed to be only about 2.7%). Therefore, the conjugation of anti-HER2-scFv would have minimal effects on the structural properties anti-HER2 scFv could not provide beneficial effects for IC7L on HER2-expressing 1 tumor accumulation. These results might be due to a fundamental feature of lactosomes 2 in effective tumor delivery by an EPR effect 8, 9 , as was also reported in previous works 3 using other nanocarrier probes that showed similar diminished effectiveness of 4 antibodies for tumor targeting 21 .
5
In contrast, compared to hIC7L, the activatable type HER2-hIC7L clearly 6 visualized tumors expressing high levels of HER2 ( Fig. 5B, D, S6 ). Since an antibody 7 used as a targeting ligand was reportedly effective for increased cellular uptake of a 8 nanocarrier probe in tumor tissue 21 , anti-HER2 scFv would also likely accelerate the 9 cellular uptake of HER2-hIC7L via interactions with HER2. This could lead to the 10 dequenching of HER2-hIC7L inside tumor cells and provide clearer tumor images than 11 hIC7L, while the total levels of HER2-hIC7L and hIC7L delivered in tumors might be 12 similar with different rates of probe accumulation in intra-and extracellular spaces in 13 tumors.
14 In recent years, other groups also produced studies on micelle-based activatable 15 probe 22 having fluorescence signals that were controlled by a self-quenching 16 mechanism that was similar to our probe. While the probes from the previous studies issue for in vivo imaging of functional molecules related to tumor malignancy (about 1 60% of dyes were released at 24 hr after incubation in an aqueous solution). We thus 2 employed a strategy wherein IC7-1 conjugated to the hydrophobic polymer of the 3 lactosome (poly-L-lactic acid; PLLA) was encapsulated to form a stable complex in the 4 lactosome core and suppressed release from the micelle 7 . On this basis, we could 5 achieve target-specifity in vivo tumor imaging.
6
In this study we adopted HER2 as a target biomolecule because HER2 is a 7 representative factor in molecular-targeted breast cancer therapy 11 and participates in 8 the signal transmission of growth factors on the cell surface followed by internalization 9 and eventual delivery to lysosomes for degradation 23 . These qualities make HER2 10 suitable for evaluating fluorescence activation strategies using lactosome probes.
11
However, this approach would not be limited to HER2, but could be applied to other modalities such as NIR endoscopic cameras 5 and clinical breast scanners 29 and is 1 expected especially to provide an informative navigation aid for surgery 30 , such 2 activatable NIR probes would be clinically powerful tools for the diagnosis of cancer 3 and other diseases. While HER2-hIC7L could visualize HER2-expressing tumors both in vitro and in 6 vivo, significant background fluorescence was also seen in the images due to 7 non-specific dequenching of hIC7L, which is in agreement with the observation that 8 quenched hIC7L was gradually dequenched after 24-hour incubation in mice plasma at 9 37 ºC (Fig. S3 ). In addition, nanocarriers with neutral or positive surface charges are 10 known to cause non-specific cell internalization as was reported in in vitro studies 31, 32 .
Although the zeta potential of our lactosome probes was estimated to be -5.0 mV, this 12 might not be sufficiently negative to avoid non-specific cellular uptake in tumors, 13 especially during the delayed phase. Therefore, the improvement of in vivo stability and 14 the introduction of negative charge on the probe surface should be considered in 15 subsequent refinement of the probes to achieve higher contrast images. benefit from activatable probes. Although a variety of activatable optical probes have 1 been developed 5 , most have excitation and emission spectra in the visible region (400 -2 700 nm) and only a few lie in the NIR region (800 -900 nm). For the two major 3 strategies used to control probe fluorescence, photoinduced electron transfer (PeT) and 4 Förster resonance energy transfer (FRET), there have been difficulties in developing 5 NIR activatable probes, which for PeT may be due to the small charge separation 6 between the highest occupied molecular orbital and the lowest unoccupied molecular 7 orbital 5, 33 , and for FRET because of the general lack of organic structures having 8 absorption around 900 -1,000 nm that is required for the regulation of 800 -900 nm 9 fluorescence 34 . Inorganic fluorescence probes such as quantum dots 35, 36 and gold 10 nanorods 37 have developed and shown promise in in vivo optical imaging; however, 11 they still invoke concerns about heavy metal toxicity 35 , though some trials have been 12 performed that avoided this potential toxicity by coating onto the probe surface with 13 biocompatible compounds such as polyethylene glycol 38, 39 and glutathione 40 . In 14 contrast, our probe is bioavailable since the lactosome is composed of the biodegradable 15 materials poly-sarcosine and poly-L-lactic acid 41, 42 , and, as with previous reports using 16 lactosomes, showed no acute or transient toxicity in treated mice in all experiments 7, 9 . safe, promising, and widely applicable probe for noninvasive in vivo diagnostic 1 techniques used to detect target biomolecules. In conclusion, we developed HER2-hIC7L that shows self-quenched fluorescence 4 and specifically interacts with HER2 expressed on tumor cells, followed by the 5 internalization in these cells, whereupon the fluorescence is dequenched after micelle 6 degradation. These results indicate that a targeting ligand such as an antibody-7 conjugated lactosome that encapsulates high concentrations of IC7-1 would be a useful 8 NIR probe that is applicable for use in noninvasive in vivo optical imaging for specific 9 detection of target biomolecules expressed in tumors.
9.
Makino A, Kizaka-Kondoh S, Yamahara R, Hara I, Kanzaki T, Ozeki E, et al. were pre-treated with 4.7 mg trastuzumab for 15 min and then treated with 11 HER2-hIC7L for 6 hr (C). Data are expressed as the FI Ratio (mean ± S.D.) for 3-4 12 samples. Comparisons between the HER2-hIC7L-treated and hIC7L-treated groups, and 13 among each concentration of trastuzumab-pretreated HER2-hIC7L and hIC7L addition 14 groups were performed with two-way factorial ANOVA followed by a Tukey-Kramer 15 test (*p < 0.01 vs. hIC7L), and with Bartlett's test followed by the Bonferroni-Holm 16 method (*p < 0.01 vs. non-trastuzumab-pretreatment HER2-hIC7L), respectively. 
Figure Legends
